LifeMine Therapeutics is developing LIFE-001, a long-acting injectable that directly binds calcineurin to prevent T-cell activation and aims to avoid the multiorgan toxicities associated with existing calcineurin inhibitors. LIFE-001 is in ongoing Phase 1 single- and multiple-ascending-dose studies involving over 120 adults and has not produced clinically meaningful renal, metabolic or cardiovascular safety signals to date. The company plans to use the new financing to fund a planned Phase 2 kidney transplant study and a Phase 1b islet cell transplant study of LIFE-001. Beyond LIFE-001, LifeMine applies a Top-Down Drug Discovery platform that leverages fungal genomic data, human genetics, bioinformatics, machine learning and synthetic biology to identify new mechanisms of action. Financially, the company has raised approximately $558 million to date. The company also strengthened its commercial leadership by appointing Yves Zinggeler as Chief Commercial Officer.

Total raised

$468M

Funding rounds

4

Latest round

Series E

Latest activity

Aug 2026